Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Combination of Micronutrients for Bone (COMB) Study: bone density after micronutrient intervention.

Genuis SJ, Bouchard TP.

J Environ Public Health. 2012;2012:354151. doi: 10.1155/2012/354151. Epub 2012 Jan 15.

2.

The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate.

Middleton ET, Steel SA, Aye M, Doherty SM.

J Bone Miner Res. 2010 Mar;25(3):455-62. doi: 10.1359/jbmr.090821.

3.

The effect of prior bisphosphonate therapy on the subsequent therapeutic effects of strontium ranelate over 2 years.

Middleton ET, Steel SA, Aye M, Doherty SM.

Osteoporos Int. 2012 Jan;23(1):295-303. doi: 10.1007/s00198-011-1547-8. Epub 2011 Jan 28.

PMID:
21274515
4.

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate.

Bruyere O, Roux C, Detilleux J, Slosman DO, Spector TD, Fardellone P, Brixen K, Devogelaer JP, Diaz-Curiel M, Albanese C, Kaufman JM, Pors-Nielsen S, Reginster JY.

J Clin Endocrinol Metab. 2007 Aug;92(8):3076-81. Epub 2007 Jun 12.

5.

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years.

Reginster JY, Bruyère O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP.

Bone. 2009 Dec;45(6):1059-64. doi: 10.1016/j.bone.2009.08.004. Epub 2009 Aug 11.

PMID:
19679207
6.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
7.

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.

N Engl J Med. 2004 Jan 29;350(5):459-68.

8.

Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis.

Rizzoli R, Laroche M, Krieg MA, Frieling I, Thomas T, Delmas P, Felsenberg D.

Rheumatol Int. 2010 Aug;30(10):1341-8. doi: 10.1007/s00296-010-1542-y. Epub 2010 May 29.

10.

Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis.

Liu JM, Wai-Chee Kung A, Pheng CS, Zhu HM, Zhang ZL, Wu YY, Xu L, Meng XW, Huang ML, Chung LP, Hussain NH, Sufian SS, Chen JL.

Bone. 2009 Sep;45(3):460-5. doi: 10.1016/j.bone.2009.05.014. Epub 2009 May 21.

PMID:
19464401
11.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005326. Review.

PMID:
17054253
12.

The use of combination therapy in the treatment of postmenopausal osteoporosis.

Compston J.

Endocrine. 2012 Feb;41(1):11-8. doi: 10.1007/s12020-011-9554-2. Epub 2011 Oct 29. Review.

PMID:
22038453
13.

[Impacts on bone mineral density].

Kurth A.

Orthopade. 2014 Feb;43(2):182. German. No abstract available.

PMID:
24693554
14.

The effects of strontium ranelate in Asian women with postmenopausal osteoporosis.

Hwang JS, Chen JF, Yang TS, Wu DJ, Tsai KS, Ho C, Wu CH, Su SL, Wang CJ, Tu ST.

Calcif Tissue Int. 2008 Nov;83(5):308-14. doi: 10.1007/s00223-008-9180-z. Epub 2008 Oct 9. Erratum in: Calcif Tissue Int. 2009 Apr;84(4):334.

PMID:
18843436
15.

Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men.

Kaufman JM, Audran M, Bianchi G, Braga V, Diaz-Curiel M, Francis RM, Goemaere S, Josse R, Palacios S, Ringe JD, Felsenberg D, Boonen S.

J Clin Endocrinol Metab. 2013 Feb;98(2):592-601. doi: 10.1210/jc.2012-3048. Epub 2013 Jan 22.

PMID:
23341486
16.

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.

Osteoporos Int. 2009 Oct;20(10):1663-73. doi: 10.1007/s00198-008-0825-6. Epub 2009 Jan 20.

17.

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.

Osteoporos Int. 2012 Mar;23(3):1115-22. doi: 10.1007/s00198-011-1847-z. Epub 2011 Nov 29.

18.

Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate.

Catalano A, Morabito N, Di Stefano A, Morini E, Basile G, Faraci B, Loddo S, Ientile R, Lasco A.

J Endocrinol Invest. 2015 Aug;38(8):859-63. doi: 10.1007/s40618-015-0299-2. Epub 2015 May 8.

PMID:
25952299
19.

Trabecular reorganization in consecutive iliac crest biopsies when switching from bisphosphonate to strontium ranelate treatment.

Jobke B, Burghardt AJ, Muche B, Hahn M, Semler J, Amling M, Majumdar S, Busse B.

PLoS One. 2011;6(8):e23638. doi: 10.1371/journal.pone.0023638. Epub 2011 Aug 16.

20.

Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.

Geller JL, Hu B, Reed S, Mirocha J, Adams JS.

Endocr Pract. 2008 Apr;14(3):293-7.

PMID:
18463035

Supplemental Content

Support Center